EUVIMEDEUVIMED entdecken
Crossref

Development of Single-Administration Burkholderia pseudomallei Vaccines using Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) Technology 2259779

Michael Davies, Taloria Wheeler, Sergei Biryukov, Christopher Klimko, Jennifer Dankmeyer, Jennifer Shoe, Melissa Hunter, Nathaniel Rill, Wendy Webster-Zahnow, Andre Swamotz, Brian Smith, Yunuen Hernandez-Viezcas und 10 weitere

The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)

DOI: 10.1093/jimmun/vkag141.783 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Michael Davies und 21 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Melioidosis, an infectious disease caused by Burkholderia pseudomallei (Bp), is difficult to treat due to intrinsic antibiotic resistance, latency with subsequent recrudescence and a diverse non-specific symptomatology. A vaccine is needed to effectively control this disease burden around the globe. Here we tested the efficacy of a novel Bp vaccine containing hemolysin-coregulated protein (Hcp1), capsular polysaccharide (CPS)-CRM197 conjugate, and CpG using the Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) platform.

Methods

C57BL/6 mice were vaccinated and the protective efficacy as well as immunological profiles were evaluated pre- and post-aerosol challenge with B. pseudomallei K96243 strain.

Results

Each tested dose of Bp ALTA® formulation demonstrated protective efficacy (20-50%) over a non-vaccinated control. Mechanistically, the Bp ALTA® formulations increased Hcp1-directed IFN-gamma recall in splenocytes, and produced robust antibody response against the principal dominant antigen, CPS. High levels of anti-CPS antibodies were associated with significant decrease in bacterial burden in the lung.

Conclusion

The ALTA® platform, which has previously been shown to provide antigen thermostability, was utilized in this study for Bp vaccination achieving protective efficacy from a single-shot administration. Studies are ongoing to optimize the immunogenic potential and protective capacity of these novel formulations. Funding Source DTRA-JSTO Topic Categories Vaccines and Immunotherapy (VAC)

Zitieren

APA

Davies, M., Wheeler, T., Biryukov, S., Klimko, C., Dankmeyer, J., Shoe, J., Hunter, M., Rill, N., Webster-Zahnow, W., Swamotz, A., Smith, B., Hernandez-Viezcas, Y., Rodriguez, C., Weiby, S., Sengyee, S., Ivanova, D., Brubaker, S., Erickson, K., Burtnick, M., …, & Cote, C. (2026). Development of Single-Administration Burkholderia pseudomallei Vaccines using Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) Technology 2259779. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.783

Vancouver

Davies M, Wheeler T, Biryukov S, Klimko C, Dankmeyer J, Shoe J, et al. Development of Single-Administration Burkholderia pseudomallei Vaccines using Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) Technology 2259779. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.783

BibTeX
@article{Davies2026,
  author = {Davies, Michael and Wheeler, Taloria and Biryukov, Sergei and Klimko, Christopher and Dankmeyer, Jennifer and Shoe, Jennifer and Hunter, Melissa and Rill, Nathaniel and Webster-Zahnow, Wendy and Swamotz, Andre and Smith, Brian and Hernandez-Viezcas, Yunuen and Rodriguez, Carlos and Weiby, Sandra and Sengyee, Sineenart and Ivanova, Daria and Brubaker, Sky and Erickson, Kimberly and Burtnick, Mary and Brett, Paul and Qiu, Ju and Cote, Christopher},
  title = {Development of Single-Administration Burkholderia pseudomallei Vaccines using Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) Technology 2259779},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {Supplement_1},
  doi = {10.1093/jimmun/vkag141.783}
}
Kostenlos starten →